NCT04620967 is a Phase 4 clinical trial of Insulin aspart in Type 1 Diabetes, sponsored by Kirsten Nørgaard.

Who is sponsoring NCT04620967?

NCT04620967 is sponsored by Kirsten Nørgaard.

What drugs are being tested in NCT04620967?

Interventions in NCT04620967: Insulin aspart, Fast-acting insulin aspart.

What condition does NCT04620967 study?

NCT04620967 studies Type 1 Diabetes.

Is NCT04620967 still recruiting?

NCT04620967 is currently status unknown. Last updated 16 February 2021.

Last reviewed 2021-02-16 · How we verify

NCT04620967

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fast-Acting Insulin Aspart and Insulin Pump Settings

Status unknown Phase 4 Last updated 16 February 2021

What this trial tests

Phase 4 trial testing Insulin aspart in Type 1 Diabetes in 40 participants. Status unknown.

Timeline

1 February 2021

Primary endpoint
30 June 2022

30 June 2022

Quick facts

Lead sponsor	Kirsten Nørgaard
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	triple
Primary purpose	treatment
Enrollment	40
Start date	1 February 2021
Primary completion	30 June 2022
Estimated completion	30 June 2022
Sites	1 location across Denmark

Drugs / interventions tested

Insulin aspart (INSULIN ASPART) — full drug profile →
Fast-acting insulin aspart — full drug profile →

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

Kirsten Nørgaard

Who can join

18 and older, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To clarify the role of fast-acting insulin aspart (Fiasp) in insulin pump-treated type 1 diabetes more research is needed. The aim of this study is twofold: 1. to compare the effects of Fiasp and Iasp in adults with type 1 diabetes who are using insulin pump and CGM and who are attending a diabetes out-patient clinic with extensive expertise in insulin pump and CGM therapy. 2. to determine differences in insulin pump settings when insulin pumps are optimally adjusted to each of the two insulin types.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Insulin aspart

Trials testing the same drug.

NCT07076199 — A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insuli · Phase 3 · recruiting
NCT06809621 — A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insul · Phase 1 · completed
NCT05946798 — Role of NADPH Oxidase in Microvascular Dysfunction Following GDM · EARLY_PHASE1 · recruiting
NCT06127433 — The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucos · Phase 4 · unknown
NCT05104424 — The Study of Quadruple Therapy Intranasal Insulin, Zinc, Gabapentin, Ice Cube Stimulation for Post COVID-19 Smell and Ta · Phase 1 · unknown

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04620967 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kirsten Nørgaard
Last refreshed: 16 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04620967.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing